Extended Data Figure 9: Anti-CD36 neutralizing antibodies inhibit metastatic initiation, and cause metastatic regression of oral SCC.
From: Targeting metastasis-initiating cells through the fatty acid receptor CD36
a, BLI quantification of tumours from mice treated with anti-CD36 FA6.152 (anti-CD36 FA6.152, n = 3 mice; IgG1, n = 3 mice; **P = 0.004, two-tailed t-test). b, d, BLI monitoring of tumours from mice treated daily with anti-CD36 JC63.1 (anti-CD36: n = 5 mice; anti-IgA isotype control, n = 5 mice). Graphs show the BLI signal quantification (*P = 0.04, two-tailed t-test). c, Representative pictures of metastatic lymph nodes of animals treated daily with JC63.1 or IgA for 2.5 weeks. e, Activated caspase-3 immunostaining of metastatic lymph nodes of Detroit-562 transplants from mice treated with monoclonal anti-CD36 JC63.1 (10 μg per 100 μl), or with the IgA isotype control. f, BLI monitoring of immunocompetent C3H/HeJ mice treated daily with monoclonal JC63.1 or IgA. Graphs show BLI signals from tumours (*P = 0.05, two-tailed t-test). g, Fold change in metastasis BLI signal of the animals reported in d. h, Representative haematoxylin and eosin staining of liver, spleen, thymus and kidney of mice from f. No pathological differences related to anti-CD36 treatment were found (n = 10 animals per group). Data in a, d, f, g are given as the mean ± s.e.m.
